Afaf H. Al-Nadaf , Areej Awadallah , Sanaa Bardaweel. Raloxifene’s in vitro anticancer effects against MCF-7 cells were facilitated by cholesterol-PEG functionalized mesoporous silica nanoparticles. Journal of Drug Delivery Science and Technology 86 (2023) 104736.

ABSTRACT:

This work offered a unique approach to delivering Raloxifene by coating Mesoporous nanoparticles with polyethylene glycol in addition to cholesterol. The cytotoxic properties of produced nanoparticles were tested against MCF-7 breast cancer cells. MCF-7 cells enable the development of differentiating, estrogen-responsive structures that are important for the assessment of estrogenic substances. FTIR, DLS, and PI were employed to examine surface characteristics. Encapsulation efficiency, in vitro release, and cytotoxic activity against MCF-7 cells, in addition to PC3 and A549 cells were evaluated. DLS confirms the size enlargement while FTIR confirms the surface decoration for the newly developed RX/Chol-PEG-MSNP system. Stability was improved and confirmed by PI change. High entrapment efficiency achieved. The cytotoxicity study on the MCF-7 cell line yielded an IC50 of 10.85 folds higher in favor of the optimized formulation. Moreover, prolonged RX release. RX/Chol-PEGMSNP induced the greatest cytotoxicity against MCF-7 cells. Docking studies confirmed Cholesterol mER interaction. This study was the first to evaluate the effectiveness of RX’s Chol-PEG-MSNP against breast cancer cells and showed its specific cytotoxic potential.